AstraZeneca’s ($AZN) MedImmune is joining the likes of Vanderbilt University and GlaxoSmithKline ($GSK) as a member of the Human Vaccines Project, the company announced Tuesday.
The public-private partnership, incubated at the International AIDS Vaccine Initiative (IAVI), aims to accelerate the development of vaccines and immunotherapies against major infectious diseases and cancers “by decoding the human immune system.”